|Title:||Method of producing FR901228|
|Abstract:|| Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.|
|Inventor(s):|| Ueda; Satoshi (Chuo-ku, JP), Watamoto; Yoko (Chuo-ku, JP), Tsuboi; Masaru (Chuo-ku, JP), Kanda; Munekazu (Chuo-ku, JP), Higaki; Tomoji (Chuo-ku, JP), Matsuda; Mitsunori (Chuo-ku, JP) |
|Assignee:|| ASTELLAS PHARMA INC. (Chuo-ku, JP) |
|Filing Date:||Apr 21, 2015|
|Claims:||1. A method of producing type A crystalline form of FR901228: ##STR00002## comprising: culturing a producing strain for FR901228 in a medium to which at least one amino acid selected from the group consisting of L-arginine, an acid addition salt of L-arginine, L-histidine, an acid addition salt of L-histidine, L-cystine, an acid addition salt of L-cystine, L-cysteine, and an acid addition salt of L-cysteine, has been added; isolating and purifying FR901228 from the medium; and crystallizing to obtain the type A crystalline form of FR901228 from a solution of FR901228 comprising ethanol and water, or acetone and water. |
2. The method of claim 1, wherein the type A crystalline form of FR901228 exhibits a powder X-ray diffraction pattern substantially similar to FIG. 3.
3. The method of claim 1, wherein the at least one amino acid comprises at least one of L-cysteine and an acid addition salt thereof in an amount greater than other amino acids.